JP2014512363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512363A5 JP2014512363A5 JP2014504058A JP2014504058A JP2014512363A5 JP 2014512363 A5 JP2014512363 A5 JP 2014512363A5 JP 2014504058 A JP2014504058 A JP 2014504058A JP 2014504058 A JP2014504058 A JP 2014504058A JP 2014512363 A5 JP2014512363 A5 JP 2014512363A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- masp
- mbl
- wallis
- letter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473698P | 2011-04-08 | 2011-04-08 | |
| US61/473,698 | 2011-04-08 | ||
| PCT/US2012/032650 WO2012139081A2 (en) | 2011-04-08 | 2012-04-06 | Methods for treating conditions associated with masp-2 dependent complement activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095034A Division JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512363A JP2014512363A (ja) | 2014-05-22 |
| JP2014512363A5 true JP2014512363A5 (enExample) | 2014-09-11 |
| JP5937197B2 JP5937197B2 (ja) | 2016-06-22 |
Family
ID=46966283
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504058A Active JP5937197B2 (ja) | 2011-04-08 | 2012-04-06 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2016095034A Active JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2017209894A Active JP6584476B2 (ja) | 2011-04-08 | 2017-10-31 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2019160040A Active JP6893539B2 (ja) | 2011-04-08 | 2019-09-03 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095034A Active JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2017209894A Active JP6584476B2 (ja) | 2011-04-08 | 2017-10-31 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2019160040A Active JP6893539B2 (ja) | 2011-04-08 | 2019-09-03 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US8951522B2 (enExample) |
| EP (3) | EP2694108B1 (enExample) |
| JP (4) | JP5937197B2 (enExample) |
| KR (6) | KR102217658B1 (enExample) |
| CN (3) | CN110075294A (enExample) |
| AU (1) | AU2012239889B2 (enExample) |
| BR (1) | BR112013025917A2 (enExample) |
| CA (4) | CA3237802A1 (enExample) |
| CL (1) | CL2013002874A1 (enExample) |
| DK (2) | DK2694108T3 (enExample) |
| ES (2) | ES2683307T3 (enExample) |
| IL (3) | IL228758B (enExample) |
| MX (3) | MX339002B (enExample) |
| NZ (5) | NZ617298A (enExample) |
| PL (1) | PL3287142T3 (enExample) |
| RU (2) | RU2743409C2 (enExample) |
| WO (1) | WO2012139081A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0688182B2 (ja) | 1986-09-08 | 1994-11-09 | バブコツク日立株式会社 | スタツド着脱装置 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| DK2694108T3 (en) | 2011-04-08 | 2018-08-20 | Univ Leicester | METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| SG10201703249PA (en) * | 2011-12-21 | 2017-05-30 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| NZ629675A (en) * | 2012-04-06 | 2017-02-24 | Omeros Corp | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria |
| PT2861246T (pt) * | 2012-06-18 | 2021-04-05 | Univ Leicester | Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| CA2906096C (en) * | 2013-03-15 | 2022-03-15 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| RS61351B1 (sr) * | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
| BR122021025449B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| SMT202100688T1 (it) | 2015-01-28 | 2022-01-10 | Ra Pharmaceuticals Inc | Modulatori di attività del complemento |
| EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| CN117398458A (zh) | 2015-11-09 | 2024-01-16 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| KR20260070290A (ko) | 2015-12-16 | 2026-05-18 | 유씨비 홀딩스 인코포레이티드 | 보체 활성의 조절인자 |
| LT3394089T (lt) * | 2015-12-23 | 2021-11-25 | eleva GmbH | Polipeptidai, skirti komplemento aktyvacijos inhibicijai |
| CA3010593C (en) * | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| NZ745531A (en) | 2016-03-31 | 2020-09-25 | Omeros Corp | Methods for inhibiting angiogenesis in a subject in need thereof |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| AU2017342428B2 (en) * | 2016-10-13 | 2021-02-04 | Omeros Corporation | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a Nephropathy |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| JP6442703B2 (ja) * | 2016-12-26 | 2018-12-26 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
| KR20190128674A (ko) * | 2017-03-09 | 2019-11-18 | 쿄와 기린 가부시키가이샤 | Masp2의 발현을 억제하는 핵산 |
| US20210093654A1 (en) * | 2017-07-28 | 2021-04-01 | Lemonex Inc. | Pharmaceutical composition for preventing or treating liver cancer |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| BR112020010916A2 (pt) | 2017-12-04 | 2020-11-17 | Ra Pharmaceuticals, Inc | moduladores da atividade do complemento |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| WO2019231935A1 (en) | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| RU2699040C1 (ru) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Способ экстренной профилактики и лечения острой лучевой болезни (варианты) |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| EP3628735A1 (en) * | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| MX2021005758A (es) * | 2018-11-15 | 2021-09-21 | Ionis Pharmaceuticals Inc | Moduladores de la expresión de irf5. |
| CA3124730A1 (en) * | 2018-12-25 | 2020-07-02 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Small rna medicament for prevention and treatment of inflammation-related diseases and combinations thereof |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| JP2022524078A (ja) | 2019-03-08 | 2022-04-27 | ラ ファーマシューティカルズ インコーポレイテッド | 深部組織浸透性ｃ５阻害剤としてのジルコプラン |
| EP3981431A4 (en) * | 2019-03-14 | 2023-06-28 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
| JP2022527508A (ja) | 2019-03-29 | 2022-06-02 | ラ ファーマシューティカルズ インコーポレイテッド | 補体モジュレータ及び関連方法 |
| CN113710230A (zh) | 2019-04-24 | 2021-11-26 | Ra制药公司 | 用于调节补体活性的组合物和方法 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113614230B (zh) * | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| ES2973767T3 (es) | 2019-06-04 | 2024-06-24 | Ra Pharmaceuticals Inc | Tratamiento de enfermedades inflamatorias con inhibidores del complemento |
| CN111024947A (zh) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | 白色念珠菌荧光免疫层析测定试剂盒及其制备方法 |
| EP4050957B1 (en) | 2019-11-27 | 2024-03-06 | Kyocera Corporation | Method and apparatus for avoiding paging collisions in a multi-sim user equipment |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CN115052862A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| AU2020395306B2 (en) | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| EP4107165A4 (en) * | 2020-02-19 | 2025-05-21 | Alnylam Pharmaceuticals, Inc. | Mannan-binding lectin-serine peptide-2 (MASP2) RNA compositions and methods of using them |
| KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
| CN115667925A (zh) * | 2020-05-15 | 2023-01-31 | 阿雷克森制药公司 | 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途 |
| CN113674860B (zh) * | 2020-05-15 | 2024-05-17 | 北京大学人民医院 | 一种难治性iTTP风险预测装置、系统及其应用 |
| WO2021257480A2 (en) | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN120173119B (zh) * | 2020-12-16 | 2025-09-30 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| WO2022228364A1 (zh) * | 2021-04-25 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 抗masp2抗体、其抗原结合片段及医药用途 |
| CA3240483A1 (en) | 2021-12-10 | 2023-06-15 | Thomas Dudler | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| CA3262515A1 (en) * | 2022-07-25 | 2024-02-01 | Amgen Inc. | ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN119978131B (zh) * | 2025-04-15 | 2025-06-27 | 北京赛斯维德生物科技有限公司 | 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69030172T2 (de) | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Impfstoffe gegen Krebs und Infektionskrankheiten |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| JP2002532079A (ja) | 1998-12-15 | 2002-10-02 | ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド | 補体活性化に関連するレクチン補体経路を調節するための方法および産物 |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| CN1402642A (zh) | 1999-07-21 | 2003-03-12 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| RU2002113381A (ru) | 1999-12-02 | 2004-01-27 | Дженс Христиан ДЖЕНСЕНИУС (DK) | MASP-3, комплемент-связывающий фермент и его применение |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| JP5226169B2 (ja) | 2000-07-13 | 2013-07-03 | ヘリオン バイオテック アンパーツゼルスカブ | Ｍａｓｐ−２、すなわち補体固定酵素及びその使用 |
| EP1416962A4 (en) | 2001-07-26 | 2006-05-24 | Alexion Pharma Inc | METHOD FOR IMPROVING THE COGNITIVE FUNCTION |
| MXPA04007124A (es) | 2002-02-01 | 2004-10-29 | Omeros Corp | Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago. |
| AU2003223288A1 (en) | 2002-03-18 | 2003-10-08 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| EP1531757B1 (en) | 2002-07-19 | 2016-09-07 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| ES2397574T3 (es) | 2002-07-30 | 2013-03-08 | Omeros Corporation | Procedimiento y soluciones de irrigación oftalmológica |
| ITRM20020511A1 (it) * | 2002-10-09 | 2004-04-10 | Santa Anna Acuto | Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi. |
| EP1570075A2 (en) | 2002-12-03 | 2005-09-07 | Aarhus Universitet | Method for determing predisposition to manifestation of immune system related diseases |
| AU2004216176B2 (en) | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| CA2519258C (en) * | 2003-03-17 | 2014-04-22 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Construct comprising region recognized by antibody against von willebrand factor-specific cleaving protease |
| HUE034760T2 (en) | 2003-05-12 | 2018-02-28 | Helion Biotech Aps | Masp-2-T binding antibodies |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP2465534B1 (en) | 2004-06-10 | 2017-03-29 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| DK1902141T3 (da) * | 2005-06-17 | 2012-05-07 | Baxter Int | ADAMTS 13-holdige sammensætninger med thrombolytisk virkning |
| EP1987354B1 (en) | 2006-01-27 | 2010-11-03 | Rappaport Family Institute for Research in the Medical Sciences | Methods for determining blood coagulation |
| DK1991275T3 (en) | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| JP6223659B2 (ja) * | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| CA2767755C (en) | 2009-07-17 | 2021-10-12 | Rigshospitalet | Inhibitors of complement activation |
| EP3150635A3 (en) | 2009-10-16 | 2017-06-21 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| CN102958535A (zh) * | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
| WO2011109338A1 (en) | 2010-03-01 | 2011-09-09 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating degos' disease |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| DK2694108T3 (en) | 2011-04-08 | 2018-08-20 | Univ Leicester | METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| PT2861246T (pt) | 2012-06-18 | 2021-04-05 | Univ Leicester | Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações |
| RS61351B1 (sr) | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| CN117398458A (zh) | 2015-11-09 | 2024-01-16 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| NZ745531A (en) * | 2016-03-31 | 2020-09-25 | Omeros Corp | Methods for inhibiting angiogenesis in a subject in need thereof |
| JPWO2018070521A1 (ja) * | 2016-10-14 | 2019-08-15 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
-
2012
- 2012-04-06 DK DK12767899.3T patent/DK2694108T3/en active
- 2012-04-06 NZ NZ617298A patent/NZ617298A/en unknown
- 2012-04-06 RU RU2018125514A patent/RU2743409C2/ru active
- 2012-04-06 KR KR1020197037437A patent/KR102217658B1/ko active Active
- 2012-04-06 WO PCT/US2012/032650 patent/WO2012139081A2/en not_active Ceased
- 2012-04-06 CA CA3237802A patent/CA3237802A1/en active Pending
- 2012-04-06 PL PL17191208T patent/PL3287142T3/pl unknown
- 2012-04-06 NZ NZ746139A patent/NZ746139A/en unknown
- 2012-04-06 CN CN201910000825.6A patent/CN110075294A/zh active Pending
- 2012-04-06 NZ NZ717517A patent/NZ717517A/en unknown
- 2012-04-06 CA CA2832187A patent/CA2832187C/en active Active
- 2012-04-06 RU RU2013149792A patent/RU2662563C2/ru active
- 2012-04-06 EP EP12767899.3A patent/EP2694108B1/en active Active
- 2012-04-06 NZ NZ731596A patent/NZ731596A/en unknown
- 2012-04-06 NZ NZ709997A patent/NZ709997A/en unknown
- 2012-04-06 MX MX2013011721A patent/MX339002B/es active IP Right Grant
- 2012-04-06 ES ES12767899T patent/ES2683307T3/es active Active
- 2012-04-06 CA CA3076975A patent/CA3076975C/en active Active
- 2012-04-06 KR KR1020217004368A patent/KR20210021101A/ko not_active Ceased
- 2012-04-06 EP EP17191208.2A patent/EP3287142B1/en active Active
- 2012-04-06 CN CN201710646474.7A patent/CN107638565B/zh active Active
- 2012-04-06 DK DK17191208.2T patent/DK3287142T3/da active
- 2012-04-06 EP EP21188935.7A patent/EP3964233A1/en active Pending
- 2012-04-06 KR KR1020227010108A patent/KR20220044616A/ko not_active Ceased
- 2012-04-06 MX MX2016006039A patent/MX355648B/es unknown
- 2012-04-06 CN CN201280028263.2A patent/CN103781492A/zh active Pending
- 2012-04-06 AU AU2012239889A patent/AU2012239889B2/en active Active
- 2012-04-06 CA CA2977009A patent/CA2977009C/en active Active
- 2012-04-06 KR KR1020137029501A patent/KR101720562B1/ko active Active
- 2012-04-06 US US13/441,827 patent/US8951522B2/en active Active
- 2012-04-06 ES ES17191208T patent/ES2894342T3/es active Active
- 2012-04-06 BR BR112013025917A patent/BR112013025917A2/pt not_active Application Discontinuation
- 2012-04-06 KR KR1020187017317A patent/KR20180072851A/ko not_active Ceased
- 2012-04-06 KR KR1020177007747A patent/KR101870915B1/ko active Active
- 2012-04-06 MX MX2018005314A patent/MX381987B/es unknown
- 2012-04-06 JP JP2014504058A patent/JP5937197B2/ja active Active
-
2013
- 2013-10-06 IL IL228758A patent/IL228758B/en active IP Right Grant
- 2013-10-07 CL CL2013002874A patent/CL2013002874A1/es unknown
-
2014
- 2014-12-23 US US14/581,191 patent/US20150239985A1/en not_active Abandoned
-
2016
- 2016-05-11 JP JP2016095034A patent/JP6239030B2/ja active Active
- 2016-12-07 US US15/371,726 patent/US10202465B2/en active Active
-
2017
- 2017-10-31 JP JP2017209894A patent/JP6584476B2/ja active Active
-
2018
- 2018-12-17 US US16/222,188 patent/US20190292272A1/en not_active Abandoned
-
2019
- 2019-01-09 IL IL264172A patent/IL264172B/en unknown
- 2019-09-03 JP JP2019160040A patent/JP6893539B2/ja active Active
-
2020
- 2020-04-23 IL IL274206A patent/IL274206A/en unknown
-
2021
- 2021-09-09 US US17/470,386 patent/US20220089781A1/en not_active Abandoned
-
2025
- 2025-05-21 US US19/214,532 patent/US20260062498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| JP2023544834A5 (enExample) | ||
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| EA201190326A8 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| JP2017528419A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| CY1116099T1 (el) | Πρωτεϊνη συντηξης κατα του καρκινου | |
| BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
| EA201590543A1 (ru) | Основанные на фибронектине каркасные доменные белки, которые связываются с миостатином | |
| CY1117710T1 (el) | Κρυσταλλικοι αναστολεις πρωτεασων εποξυ-κετονων πεπτιδιων και η συνθεση των κετο-εποξειδιων αμινοξεων | |
| MX379069B (es) | Vacunas terapeuticas contra el vph16. | |
| WO2009108261A3 (en) | Compositions and methods for the treatment of viral infections | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| IN2014CN00414A (enExample) | ||
| EA200870237A1 (ru) | Последовательности пептидов и композиции | |
| JP2019500414A5 (enExample) | ||
| ATE539089T1 (de) | Cyclische rezeptor-assoziierte-proteine (rap)- peptide | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| JP2018538356A5 (enExample) | ||
| NZ769391A (en) | Serpin fusion polypeptides and methods of use thereof | |
| EP4481045A3 (en) | Dna-binding protein using ppr motif, and use thereof | |
| ATE500265T1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie |